YB-1 Activating Cascades As Potential Targets in KRAS-mutated Tumors

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2023 Jun 2

PMID 37268766

Authors

Shayan Khozooei

Soundaram Veerappan

Mahmoud Toulany

Affiliations

Soon will be listed here.

Abstract

Y‑box binding protein‑1 (YB-1) is a multifunctional protein that is highly expressed in human solid tumors of various entities. Several cellular processes, e.g. cell cycle progression, cancer stemness and DNA damage signaling that are involved in the response to chemoradiotherapy (CRT) are tightly governed by YB‑1. KRAS gene with about 30% mutations in all cancers, is considered the most commonly mutated oncogene in human cancers. Accumulating evidence indicates that oncogenic KRAS mediates CRT resistance. AKT and p90 ribosomal S6 kinase are downstream of KRAS and are the major kinases that stimulate YB‑1 phosphorylation. Thus, there is a close link between the KRAS mutation status and YB‑1 activity. In this review paper, we highlight the importance of the KRAS/YB‑1 cascade in the response of KRAS-mutated solid tumors to CRT. Likewise, the opportunities to interfere with this pathway to improve CRT outcome are discussed in light of the current literature.

Citing Articles

A comprehensive view on the fisetin impact on colorectal cancer in animal models: Focusing on cellular and molecular mechanisms.

Zamanian M, Taheri N, Ramadan M, Mustafa Y, Alkhayyat S, Sergeevna K Animal Model Exp Med. 2024; 7(5):591-605.

PMID: 39136058 PMC: 11528395. DOI: 10.1002/ame2.12476.

Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer.

Karachaliou A, Kotteas E, Fiste O, Syrigos K Cancers (Basel). 2024; 16(8).

PMID: 38672529 PMC: 11048139. DOI: 10.3390/cancers16081447.

Future prospects in radiation oncology from the perspective of innovative radiation biology.

Rodel F, Gaipl U Strahlenther Onkol. 2023; 199(12):1077-1079.

PMID: 38001382 PMC: 10673720. DOI: 10.1007/s00066-023-02163-w.

References

Dolfini D, Mantovani R . Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y?. Cell Death Differ. 2013; 20(5):676-85. PMC: 3619239. DOI: 10.1038/cdd.2013.13. View

Lindquist J, Mertens P . Cold shock proteins: from cellular mechanisms to pathophysiology and disease. Cell Commun Signal. 2018; 16(1):63. PMC: 6158828. DOI: 10.1186/s12964-018-0274-6. View

Zhan Y, Chen X, Zheng H, Luo J, Yang Y, Ning Y . YB1 associates with oncogenetic roles and poor prognosis in nasopharyngeal carcinoma. Sci Rep. 2022; 12(1):3699. PMC: 8904596. DOI: 10.1038/s41598-022-07636-z. View

Yahata H, Kobayashi H, Kamura T, Amada S, Hirakawa T, Kohno K . Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol. 2002; 128(11):621-6. DOI: 10.1007/s00432-002-0386-6. View

Nishio S, Ushijima K, Yamaguchi T, Sasajima Y, Tsuda H, Kasamatsu T . Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer. Gynecol Oncol. 2014; 132(3):703-8. DOI: 10.1016/j.ygyno.2014.01.045. View

Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E . Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer. 2009; 9:410. PMC: 2788584. DOI: 10.1186/1471-2407-9-410. View

Fushimi F, Taguchi K, Izumi H, Kohno K, Kuwano M, Ono M . Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma. Virchows Arch. 2013; 463(4):553-62. DOI: 10.1007/s00428-013-1460-y. View

Sheridan C, Grogan T, Nguyen H, Galet C, Rettig M, Hsieh A . YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence. Oncotarget. 2015; 6(10):7470-80. PMC: 4480693. DOI: 10.18632/oncotarget.3477. View

Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K . Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001; 7(10):3151-5. View

10.

Guo T, Zhao S, Wang P, Xue X, Zhang Y, Yang M . YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma. Oncotarget. 2017; 8(29):48110-48125. PMC: 5564630. DOI: 10.18632/oncotarget.18262. View

11.

Sinnberg T, Sauer B, Holm P, Spangler B, Kuphal S, Bosserhoff A . MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop. Exp Dermatol. 2012; 21(4):265-70. DOI: 10.1111/j.1600-0625.2012.01448.x. View

12.

Song Y, Shiota M, Yokomizo A, Uchiumi T, Kiyoshima K, Kuroiwa K . Twist1 and Y-box-binding protein-1 are potential prognostic factors in bladder cancer. Urol Oncol. 2013; 32(1):31.e1-7. DOI: 10.1016/j.urolonc.2012.11.003. View

13.

Yan X, Yan L, Zhou J, Liu S, Shan Z, Jiang C . High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer. Int J Clin Exp Pathol. 2015; 7(12):8715-23. PMC: 4314019. View

14.

Zhang Y, Reng S, Wang L, Lu L, Zhao Z, Zhang Z . Overexpression of Y-box binding protein-1 in cervical cancer and its association with the pathological response rate to chemoradiotherapy. Med Oncol. 2011; 29(3):1992-7. DOI: 10.1007/s12032-011-0062-2. View

15.

Mylona E, Melissaris S, Giannopoulou I, Theohari I, Papadimitriou C, Keramopoulos A . Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse. Eur J Surg Oncol. 2013; 40(3):289-96. DOI: 10.1016/j.ejso.2013.09.008. View

16.

Shibahara K, Uchiumi T, Fukuda T, Kura S, Tominaga Y, Maehara Y . Targeted disruption of one allele of the Y-box binding protein-1 (YB-1) gene in mouse embryonic stem cells and increased sensitivity to cisplatin and mitomycin C. Cancer Sci. 2004; 95(4):348-53. PMC: 11159763. DOI: 10.1111/j.1349-7006.2004.tb03214.x. View

17.

Chatterjee M, Rancso C, Stuhmer T, Eckstein N, Andrulis M, Gerecke C . The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood. 2007; 111(7):3714-22. DOI: 10.1182/blood-2007-05-089151. View

18.

Kim E, Selyutina A, Buldakov I, Evdokimova V, Ovchinnikov L, Sorokin A . The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA damaging stress. Cell Cycle. 2013; 12(24):3791-803. PMC: 3905071. DOI: 10.4161/cc.26670. View

19.

Johnson T, Schelch K, Mehta S, Burgess A, Reid G . Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma. Front Cell Dev Biol. 2019; 7:221. PMC: 6781797. DOI: 10.3389/fcell.2019.00221. View

20.

Kohno Y, Matsuki Y, Tanimoto A, Izumi H, Uchiumi T, Kohno K . Expression of Y-box-binding protein dbpC/contrin, a potentially new cancer/testis antigen. Br J Cancer. 2006; 94(5):710-6. PMC: 2361212. DOI: 10.1038/sj.bjc.6602987. View